Abstract 526P
Background
Tracheal, Bronchus, and Lung (TBL) cancer is the 1st leading cause of deaths across Southeast Asia (SEA), East Asia (EA), and Oceania (OC). However, there has been a lack of estimates regarding the burden of TBL cancer across these regions in previous studies.
Methods
Utilizing the Global Burden of Disease Methodology, TBL cancer prevalence, incidence, mortality, and disabiity adjusted life years (DALYs) were analyzed by age, sex, year, across SEA, EA, and OC spanning from 1990-2019. We employed a regression framework to forecast TBL cancer deaths through 2040.
Results
The total prevalence of TBL cancer cases surged by 3.5 times, escalating from 344,251 (95% uncertainty interval: 301,687-388,590) in 1990 to 1,306,745 (1,116,313-1,513,254) in 2019. While deaths rose from 319,128 (282,904-359,206) to 914,442 (791,095-1,049,894) from 1990-2019. In terms of the age-standardized incidence rate (ASIR), there was an increase from 27.81 (24.65-31.15) to 37.13 (32.08-42.53) per 100,000 person years from 1990-2019. The highest annual percentage of change (APC) was witnessed in deaths, rising by 187%, and in DALYs, increasing by 143% from 1990-2019. Notably, China experienced the highest APC in ASIR (38%), followed by Indonesia (35%), and Taiwan (28%) from 1990-2019. Meanwhile, Indonesia exhibited the highest increase in age-standardized mortality rate (ASMR) at 36%, while the Maldives demonstrated the most notable decrease of 33% from 1990-2019. In 2019, individuals aged 65-69 accounted for the highest incidence (172,031), while those aged 70-74 saw the highest mortality (155,538). Moreover, male individuals consistently bore a greater burden than females over the past three decades. Projection indicates that the total number of deaths may reach 1,080,050 (705,751-1,800,670) by 2040.
Conclusions
TBL cancer constituted 26.21% of all deaths within the realm of cancer-related fatalities in SEA, EA, and OC in 2019. This study uncovers a consistent pattern of escalating burden, emphasizing a notable rise in fatalities and its implications for public health, necessitates comprehensive strategies that encompass both individual risk factors and systemic challenges.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
602P - COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib (Enco) + binimetinib (Bini) vs vemurafenib (Vemu) or Enco in patients (Pts) with BRAF V600-mutant melanoma
Presenter: Andrew Haydon
Session: Poster Display
Resources:
Abstract
603P - An individualised postoperative radiological surveillance schedule for IDH-wildtype glioblastoma patients (HK-GBM Registry)
Presenter: Jason Chak Yan Li
Session: Poster Display
Resources:
Abstract
604P - Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer who progressed after prior VEGFR-targeted therapy: Outcomes from COSMIC-311 by BRAF status
Presenter: Marcia Brose
Session: Poster Display
Resources:
Abstract
606P - BRAF and NRAS mutations are associated with poor prognosis in Asians with acral-lentiginous and nodular cutaneous melanoma
Presenter: Sumadi Lukman Anwar
Session: Poster Display
Resources:
Abstract
607P - Single institutional outcomes of radiotherapy and systemic therapy for melanoma brain metastases in Japan
Presenter: Naoya Yamazaki
Session: Poster Display
Resources:
Abstract
608P - The efficacy of immune checkpoint inhibitors and targeted therapy in mucosal melanomas: A systematic review and meta-analysis
Presenter: Andrea Teo
Session: Poster Display
Resources:
Abstract
609P - The association between thyroid function abnormalities and vitiligo induced by pembrolizumab regarding prognosis in patients with advanced melanoma
Presenter: Moez Mobarek
Session: Poster Display
Resources:
Abstract
610P - Analyzing the clinical benefit of the evidence presented at these congresses and utilizing a standardized scale to quantify it will significantly enhance our understanding of the studies showcased, allowing for more objective evaluation and interpretation
Presenter: Charles Jeffrey Tan
Session: Poster Display
Resources:
Abstract
611P - ESMO-magnitude of clinical benefit scale (MCBS) scores for phase III trials of adjuvant and curative therapies at the 2022 ASCO annual meeting (ASCO22)
Presenter: Thi Thao Vi Luong
Session: Poster Display
Resources:
Abstract
612P - Is the juice worth the squeeze? Overall survival gain per unit treatment time as a metric of clinical benefit of systemic treatment in incurable cancers
Presenter: Vodathi Bamunuarachchi
Session: Poster Display
Resources:
Abstract